⚡ Flash Summary

Haleon Pakistan Limited (HALEON) reported unaudited condensed financial information for the nine months ended September 30, 2025. The company achieved a 17% year-over-year revenue growth, driven by robust demand and effective market strategies. Net profit after tax increased significantly to Rs. 4,586 million, with Earnings Per Share (EPS) rising to Rs. 39.18. Despite increased operational costs, the company is committed to improving healthcare access across Pakistan through strategic investments and leadership development.

📌 Key Takeaways

• 🚀 Revenue grew by 17% year-over-year for the first nine months of 2025.
• 💰 Net profit after tax reached Rs. 4,586 million.
• 📈 Earnings Per Share (EPS) increased to Rs. 39.18 from Rs. 27.36 in the previous year.
• 💊 Over-the-Counter (OTC) portfolio expanded by 18%.
• 🚚 Fast-Moving Consumer Goods (FMCG) segment surged by 32%.
• 📊 Total expenses to net sales ratio increased to 16.63% from 16.00%.
• 📉 Income from financial assets decreased to Rs. 608 million from Rs. 783 million.
• 🌍 Haleon contributed Rs. 27 billion (USD 98 million) in gross value added (GVA) to Pakistan’s economy in 2024.
• 🤝 Supports over 6,600 jobs nationwide.
• 🌟 Pakistan’s pharmaceutical exports hit a 20-year high of $457 million in FY25, a 34% year-over-year increase.
• 🌐 Finance executive promoted to a regional role.
• 💼 New finance lead promoted from within the organization.
• 🌱 Board of Directors approved an interim cash dividend of Rs. 5 per share.
• 🎯 Capital expenditure commitments outstanding amount to Rs. 1,192.85 million.

🎯 Investment Thesis

Based on strong financial performance, market position, and contribution to Pakistan’s economy, a BUY recommendation is justified. The company’s strategic investments, leadership development, and commitment to healthcare access support long-term growth. The target price should reflect the enhanced EPS, growth trajectory, and valuation premium relative to peers.